Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

NCT00071994 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

NIH

Sponsor class

Conditions

Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions

DRUG: gefitinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)